{"id":"ff-via-ellipta-dpi","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Oral candidiasis"}]},"_chembl":{"chemblId":"CHEMBL3975426","moleculeType":"Small molecule","molecularWeight":"488.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone furoate is a potent inhaled corticosteroid that suppresses inflammatory responses in the airways by activating glucocorticoid receptors, leading to decreased production of inflammatory mediators and reduced airway inflammation. The ELLIPTA DPI (dry powder inhaler) is a delivery device designed to optimize lung deposition of the drug. This combination is used to control asthma and COPD symptoms by reducing airway obstruction and inflammation.","oneSentence":"FF (fluticasone furoate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:29.098Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT07282886","phase":"PHASE2","title":"VENTURI (VENTilation Using Respiratory Imaging)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-15","conditions":"Asthma","enrollment":20},{"nctId":"NCT03248128","phase":"PHASE3","title":"Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-20","conditions":"Asthma","enrollment":906},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436},{"nctId":"NCT03012061","phase":"PHASE2","title":"Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-25","conditions":"Asthma","enrollment":425},{"nctId":"NCT03467425","phase":"PHASE4","title":"INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3109},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT02446418","phase":"PHASE3","title":"A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-09","conditions":"Asthma","enrollment":423},{"nctId":"NCT02218723","phase":"PHASE1","title":"Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-28","conditions":"Asthma","enrollment":30},{"nctId":"NCT02345161","phase":"PHASE3","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1811},{"nctId":"NCT02666287","phase":"PHASE1","title":"GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-01-27","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FF via ELLIPTA DPI","genericName":"FF via ELLIPTA DPI","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FF via ELLIPTA DPI is a small molecule medication used to treat asthma and chronic obstructive pulmonary disease (COPD), as well as other pulmonary diseases. It is available in various fixed-dose combinations, including FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, and FF/UMEC/VI (200/31.25/25) mcg.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}